Hemostemix Inc (TSV: HEM )

0.0900 +0.0050 (+5.88%)

Streaming Delayed Price Updated: 9:51 AM EST, Nov 12, 2024 Add to My Watchlist

Price and Volume

Volume	5,000
Open	0.0900
Bid (Size)	0.0900 (10)
Ask (Size)	0.1000 (320)
Prev. Close	0.0850
Today's Range	0.0900 - 0.0900
52wk Range	0.0350 - 0.1100
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board

September 27, 2022

Calgary, Alberta--(Newsfile Corp. - September 27, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company")...

Via Newsfile

Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board

September 20, 2022

Calgary, Alberta--(Newsfile Corp. - September 20, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company")...

Via Newsfile

Performance

YTD	+28.57%	+28.57%
1 Month	+38.46%	+38.46%
3 Month	+100.00%	+100.00%
6 Month	+125.00%	+125.00%
1 Year	+23.29%	+23.29%

More News

Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board

September 16, 2022

Via Newsfile

Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board

September 15, 2022

Via Newsfile

Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board

September 14, 2022

Via Newsfile

Hemostemix Announces Its Presentation to the Emerging Growth Conference

September 14, 2022

Via Newsfile

Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc.

September 13, 2022

Via Newsfile

Hemostemix Announces Closing of $2,750,000

April 26, 2022

Via IssueWire

Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed

April 13, 2022

Via IssueWire

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

September 14, 2021

Via Newsfile

Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results

July 06, 2021

Via Newsfile

Peter Lacey Increases His Investment in Hemostemix Inc.

June 21, 2021

Via Newsfile

Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture

June 11, 2021

Via Newsfile

Hemostemix Announces that, Due to the COVID-19 Pandemic, the Annual and Special Meeting Will Only Be Held via Zoom and Shareholders are Requested to Follow the Meeting Instructions Mailed to the Shareholders of Record

May 31, 2021

Via Newsfile

Hemostemix to Present at the Emerging Growth Conference

May 25, 2021

Via Newsfile

CEO Presenting on the Emerging Growth Conference on May 26

May 24, 2021

Via EIN Presswire

Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list

April 23, 2021

Via Newsfile

Hemostemix Announces It Is Trading on the Frankfurt Stock Exchange and It Has Retained HE Capital Markets Ltd.

April 08, 2021

Via Newsfile

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.